Dataset features

Specifications


Application: Gene expression microarray analysis
Number of samples: 54
Release date: Jan 18 2017
Last update date: Aug 13 2018
Access: Public
Chemicals: Steroids
Dataset link Differential gene expression profile correlates with bortezomib responsiveness in steroid-resistant cGVHD

Experimental Protocol


54 total samples, 0 replicates, 8 healthy controls, 6 disease controls. Sample details follow. Eligible patients were 18 years or older with a confirmed clinical diagnosis of steroid-refractory cGVHD, defined as either failure to improve after 2 months or progression after 1 month of standard steroid-based therapy, and had no prior bortezomib treatment for cGVHD. Enrolled patients were required to be in remission from his/her primary malignancy for which HSCT was indicated, ECOG performance status 50% improvement in any specific organ score or overall performance was considered partial response (PR). Disappearance of symptoms of cGVHD was considered complete response (CR). Worsening of symptoms in specific organ or overall observed in two consecutive assessment time points was considered as progressive disease (PD). All human subject-related study protocols were reviewed and approved by the institutional Review Board for Human Protection, Baylor University Medical Center. All patients signed informed consent before being enrolled into study. This trial was registered at www.clinicaltrials.gov as NCT01158105.

Repositories


GEO

GSE56495

BioProject

PRJNA243507

Download